Letter to the editor referring to the publication entitled “The
role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and
neck cancer treatment” by Pai et al.

J 2016

Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.

SZTURZ, Petr and S. FAIVRE

Basic information

Original name

Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution) and S. FAIVRE (250 France)

Edition

Oral Oncology, Amsterdam, Elsevier Science BV, 2016, 1368-8375

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Netherlands

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 4.794

RIV identification code

RIV/00216224:14110/16:00092818

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.oraloncology.2016.08.007

UT WoS

000392635300002

EID Scopus

2-s2.0-84994460785

Keywords in English

squamous-cell carcinoma; recurrent; methotrexate; trial

Abstract

V originále

As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator’s choice (single-agent chemotherapy or cetuximab) [1–4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.

Cite

SZTURZ, Petr and S. FAIVRE. Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al. Oral Oncology. Amsterdam: Elsevier Science BV, 2016, vol. 62, "neuvedeno", p. "e3"-"e4", 2 pp. ISSN 1368-8375. Available from: https://dx.doi.org/10.1016/j.oraloncology.2016.08.007.

@article{1367429,
   author = {Szturz, Petr and Faivre, S.},
   article_location = {Amsterdam},
   article_number = {"neuvedeno"},
   doi = {http://dx.doi.org/10.1016/j.oraloncology.2016.08.007},
   keywords = {squamous-cell carcinoma; recurrent; methotrexate; trial},
   language = {eng},
   issn = {1368-8375},
   journal = {Oral Oncology},
   title = {Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.},
   volume = {62},
   year = {2016}
}

TY  - JOUR
ID  - 1367429
AU  - Szturz, Petr - Faivre, S.
PY  - 2016
TI  - Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.
JF  - Oral Oncology
VL  - 62
IS  - "neuvedeno"
SP  - "e3"-"e4"
EP  - "e3"-"e4"
PB  - Elsevier Science BV
SN  - 13688375
KW  - squamous-cell carcinoma
KW  - recurrent
KW  - methotrexate
KW  - trial
N2  - As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator’s choice (single-agent chemotherapy or cetuximab) [1–4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.
ER  -

SZTURZ, Petr and S. FAIVRE. Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al. \textit{Oral Oncology}. Amsterdam: Elsevier Science BV, 2016, vol.~62, ''neuvedeno'', p.~''e3''-''e4'', 2 pp. ISSN~1368-8375. Available from: https://dx.doi.org/10.1016/j.oraloncology.2016.08.007.

Přehled o publikaci